Two-Year safety check for Kids' arthritis drug shows promise
NCT ID NCT01673919
Summary
This study followed a small group of children in France with juvenile arthritis for two years to check the long-term safety of a drug called tocilizumab. The children had already been taking the drug in a previous study and continued receiving it by IV every four weeks. The main goal was to monitor for any side effects or health problems during this extended treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Le Kremlin-Bicêtre, 94275, France
-
Study site
Montpellier, 34295, France
-
Study site
Paris, 75679, France
-
Study site
Paris, 75743, France
Conditions
Explore the condition pages connected to this study.